Catalog Number 07C18-29 |
Device Problem
High Test Results (2457)
|
Patient Problem
No Known Impact Or Consequence To Patient (2692)
|
Event Date 04/01/2018 |
Event Type
malfunction
|
Manufacturer Narrative
|
An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.There is no further patient information provided by the customer.This report is being filed on an international product, list number 7c18 that has a similar product distributed in the us, list number 1l82.
|
|
Event Description
|
The customer reported false (b)(6) architect (b)(6) results on one patient.The results provided were: (b)(6) 2017 =(b)(6) / (b)(6) 2018 = (b)(6) / (b)(6) 2019 = (b)(6).The patient has not been vaccinated.There was no reported impact to patient management.
|
|
Manufacturer Narrative
|
A review of tickets determined normal complaint activity for lot 01347fn00 and no trends were identified for the issue for the product.Return testing was not completed as returns were not available.Historical performance of reagent lot 01347fn00 was evaluated using world wide data from abbottlink.The median population result for the lot is comparable with all other lots in the field and within established baselines and confirms no systemic issue for the lot.A review of the manufacturing documentation did not identify any issues associated with the customer's observation.A review of the product labeling concluded that the issue is sufficiently addressed.The overall sensitivity of the architect anti-hbs assay was estimated to be 95.97% at the lower 95% confidence level.Therefore, false elevated and false depressed results may occur.Based on the investigation no product deficiency was identified for the architect anti-hbs reagent, lot 01347fn00.
|
|
Search Alerts/Recalls
|